Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has regained compliance with the Nasdaq's minimum closing bid price requirement, addressing one of two issues facing the company's ability to trade its stock on the exchange.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.